Fig. 5: ACSS2 or ACSS1 high expression in the AML TCGA cohort predicts poor prognosis and relates to a distinct metabolic signature.

A Kaplan-Meier estimation of the overall survival shows the poor outcome of patients in the top ACSS1/2 expression (red line, n = 20) compared to others (blue line, n = 136, log-rank test). Dotted lines mark the 95% confidence bounds. B Heatmap representation of differentially expressed genes in the TCGA AML dataset. Patients were plotted in the columns with the differential expressed genes in the rows. Top 20 ACSS1/ACSS2 expression samples (n = 20 patients) were plotted in the horizontal rows above the heat map. Groups 1 and 2 show the division of the TCGA cohort into two groups using unsupervised clustering of this gene expression matrix (K-means for 2 groups) resulting in 1226 differentially expressed genes. Genes were classified as high or low according to the average expression of a gene in Group 2. C Kaplan-Meier estimation of the overall survival shows the poor outcome of patients in Group 2 (red line) compared to Group 1 (blue line, log-rank test). Dotted lines mark the 95% confidence bounds. D Functional annotation and enrichment cluster score from DAVID Bioinformatic Resources of genes up and downregulated with ACSS1/2 high expression are plotted.